Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAD | P27708 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 8/20 | 0.39 |
| ▸ | ACE | P12821 | 4/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630497 | 1.00 | CAD (0.43) | CADMMEACEHDAC3HDAC11 | |
| SCHEMBL2344195 | 1.00 | CAD (0.43) | CADMMEACEHDAC3HDAC11 | |
| SCHEMBL6501628 | 0.94 | MME (0.44) | CADMMEACE | |
| SCHEMBL6813416 | 0.94 | MME (0.44) | CADMMEACE | |
| SCHEMBL6814128 | 0.94 | MME (0.44) | CADMMEACE | |
| SCHEMBL20367630 | 0.92 | MME (0.46) | CADMMEACE | |
| SCHEMBL15134405 | 0.92 | MME (0.46) | CADMMEACE | |
| SCHEMBL4903224 | 0.92 | MME (0.46) | CADMMEACE | |
| SCHEMBL18576543 | 0.92 | MME (0.46) | CADMMEACE | |
| Pidolic Acid SCHEMBL7554345 | 0.86 | CAD (0.46) | CADCYP2D6LMNABLMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000794-A1 | LACTAM AND LACTONE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION SUCH AS COVID-19 | Université Catholique de Louvain (BE) | 2024-01-04 | — | — | US | claimed |
| WO-2022106646-A1 | LACTAM AND LACTONE DERIVATIVES OF FORMULA (IA) FOR USE IN THE TREATMENT OF DISEASES CAUSED BY A CORONAVIRUS INFECTION AND/OR A VIRAL RESPIRATORY INFECTION | Université Catholique de Louvain (BE) | 2022-05-27 | — | — | WO | claimed |
| EP-4000620-A1 | LACTAM AND LACTONE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION SUCH AS COVID-19 | Université catholique de Louvain (BE) | 2022-05-25 | — | — | EP | claimed |
| EP-2758371-B1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA TAU IND FARMACEUTI (IT) | 2016-06-15 | — | — | EP | claimed |
| US-8927533-B2 | Thio derivatives bearing lactams as potent HDAC inhibitors and their uses as medicaments | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2015-01-06 | — | — | US | claimed |
| EP-2758371-A1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2014-07-30 | — | — | EP | claimed |
| WO-2013041480-A1 | NEW THIO DERIVATIVES BEARING LACTAMS AS POTENT HDAC INHIBITORS AND THEIR USES AS MEDICAMENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-03-28 | — | — | WO | claimed |
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| EP-4631946-A1 | SUBSTITUTED TRICYCLIC LIGANDS FOR FK506-BINDING PROTEINS FOR TREATMENT OF DISEASES | Technische Universität Darmstadt (DE) | 2025-10-15 | — | — | EP | disclosed |
| EP-4631947-A1 | SUBSTITUTED TRICYCLIC LIGANDS FOR FK506-BINDING PROTEINS FOR TREATMENT OF DISEASES | Technische Universität Darmstadt (DE) | 2025-10-15 | — | — | EP | disclosed |
| US-20250313562-A1 | Substituted tricyclic ligands for FK506-binding proteins for treatment of diseases | Technische Universität Darmstadt (DE) | 2025-10-09 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| WO-2025136961-A1 | CHEMICAL MATTERS FOR TARGETING HISTONE ACETYLTRANSFERASE P300 (EP300) AND CREB-BINDING PROTEIN (CBP) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
| EP-1069132-B1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | SERVIER LAB (FR) | 2003-10-01 | — | — | EP | disclosed |
| US-6277851-B1 | ORALLY ADMINISTERED TRYPSIN-RELATED SERINE PROTEASE INHIBITORS; ANTICOAGULANTS | ADIR ET COMPAGNIE (FR) | 2001-08-21 | — | — | US | disclosed |
| EP-1069132-A1 | Bicyclic derivatives of amino-pyrazinones, process of preparation and pharmaceutical compositions comprising them | ADIR ET COMPAGNIE (FR) | 2001-01-17 | — | — | EP | disclosed |
| US-4254261-A | USEFUL IN SELECTIVE CRYSTALLIZATION OF DIASTEREOMERS OF THE PIPERIDINE COMPOUND WHICH ARE FURTHER REQUIRED FOR MAKING TRIPEPTIDES WHICH ARE CENTRAL NERVOUS SYSTEM STIMULANTS | MERCK & CO., INC. (US) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | CAD 4448/4885MME 4209/4885ACE 1755/4885 |
| US-20250313562-A1 | Substituted tricyclic ligands for FK506-binding proteins for treatment of diseases | FKBP14, FKBP2, FKBP8 | CAD 1263/4885MME 2367/4885ACE 4580/4885 |
| US-20240000794-A1 | LACTAM AND LACTONE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION SUCH AS COVID-19 | FURIN, SARS1, IL4I1 | CAD 2652/4885MME 1525/4885ACE 11/4885 |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, CTSC, PREP | CAD 3484/4885MME 49/4885ACE 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.